BRPI0407341A - Combinação de drogas antidiabéticas - Google Patents

Combinação de drogas antidiabéticas

Info

Publication number
BRPI0407341A
BRPI0407341A BR0407341-0A BRPI0407341A BRPI0407341A BR PI0407341 A BRPI0407341 A BR PI0407341A BR PI0407341 A BRPI0407341 A BR PI0407341A BR PI0407341 A BRPI0407341 A BR PI0407341A
Authority
BR
Brazil
Prior art keywords
combination
drug combination
antidiabetic drug
drugs
antidiabetic
Prior art date
Application number
BR0407341-0A
Other languages
English (en)
Inventor
Pompeo Pessotto
Fabio Giannessi
Original Assignee
Sigma Tau Ind Famaceutiche Riu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Famaceutiche Riu filed Critical Sigma Tau Ind Famaceutiche Riu
Publication of BRPI0407341A publication Critical patent/BRPI0407341A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMBINAçãO DE DROGAS ANTIDIABéTICAS". A presente invenção refere-se a combinação de R-4-trimetilamónio-3-(tetradecilcarbamoil)-aminobutirato e metformina. A referida combinação de drogas antidiabéticas exerce uma ação sinérgica e permite a administração das duas drogas em doses tais como para evitar ou reduzir a ocorrência de efeitos colaterais. A combinação também é útil para aperfeiçoar a cobertura terapêutica longe dos horários das refeições, e na pós-absorção e condições de jejum.
BR0407341-0A 2003-02-10 2004-01-23 Combinação de drogas antidiabéticas BRPI0407341A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000053A ITRM20030053A1 (it) 2003-02-10 2003-02-10 Associazione di farmaci antidiabetici.
PCT/IT2004/000014 WO2004069239A1 (en) 2003-02-10 2004-01-23 Combination of antidiabetic drugs

Publications (1)

Publication Number Publication Date
BRPI0407341A true BRPI0407341A (pt) 2006-01-10

Family

ID=29765650

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407341-0A BRPI0407341A (pt) 2003-02-10 2004-01-23 Combinação de drogas antidiabéticas

Country Status (21)

Country Link
US (1) US20060058385A1 (pt)
EP (1) EP1592417B1 (pt)
JP (1) JP2006517223A (pt)
KR (1) KR20050098285A (pt)
CN (1) CN1741799B (pt)
AR (1) AR043129A1 (pt)
AT (1) ATE359776T1 (pt)
AU (1) AU2004210246B2 (pt)
BR (1) BRPI0407341A (pt)
CA (1) CA2512618C (pt)
CY (1) CY1106546T1 (pt)
DE (1) DE602004005966T2 (pt)
DK (1) DK1592417T3 (pt)
ES (1) ES2286595T3 (pt)
IT (1) ITRM20030053A1 (pt)
MX (1) MXPA05008336A (pt)
PL (1) PL378419A1 (pt)
PT (1) PT1592417E (pt)
SI (1) SI1592417T1 (pt)
TW (1) TWI322687B (pt)
WO (1) WO2004069239A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ603614A (en) * 2010-05-26 2014-10-31 Transtech Pharma Llc Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
US8735349B2 (en) * 2011-05-13 2014-05-27 Sanofi-Aventis Deutschland Gmbh Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1299266B1 (it) * 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi

Also Published As

Publication number Publication date
TWI322687B (en) 2010-04-01
ITRM20030053A1 (it) 2004-08-11
ITRM20030053A0 (it) 2003-02-10
CY1106546T1 (el) 2012-01-25
SI1592417T1 (sl) 2007-08-31
ES2286595T3 (es) 2007-12-01
KR20050098285A (ko) 2005-10-11
CN1741799A (zh) 2006-03-01
JP2006517223A (ja) 2006-07-20
DE602004005966D1 (de) 2007-05-31
CA2512618A1 (en) 2004-08-19
ATE359776T1 (de) 2007-05-15
EP1592417B1 (en) 2007-04-18
EP1592417A1 (en) 2005-11-09
CN1741799B (zh) 2010-05-26
PL378419A1 (pl) 2006-04-03
PT1592417E (pt) 2007-07-17
DE602004005966T2 (de) 2007-12-20
CA2512618C (en) 2011-12-13
AU2004210246B2 (en) 2009-05-07
DK1592417T3 (da) 2007-08-06
US20060058385A1 (en) 2006-03-16
TW200418450A (en) 2004-10-01
MXPA05008336A (es) 2005-11-04
AR043129A1 (es) 2005-07-20
HK1087623A1 (en) 2006-10-20
WO2004069239A1 (en) 2004-08-19
AU2004210246A1 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
BRPI0417260A (pt) derivados de azepinoindol como agentes farmacêuticos
BRPI0508461B8 (pt) diaminopirimidinas, seus usos, e composição farmacêutica
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
BR0314308A (pt) Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
BRPI0417820A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóide
BR0116607A (pt) Derivados de glicopiranosiloxipirazol e uso dos mesmos em medicamentos
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
UY26130A1 (es) Compuestos para tratar la obesidad
BRPI0418026A (pt) derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
CA2505128A1 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
BR0209957A (pt) Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
EP2460522A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BRPI0412343A (pt) derivados de piridazina e seu uso como agentes terapêuticos
BRPI0514357A (pt) combinações para o tratamento de doenças que envolvem a proliferação de células
MX2007005570A (es) Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos.
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BRPI0509298A (pt) composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto
BRPI0412919A (pt) combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
BR0014946A (pt) Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina
BRPI0408295A (pt) uso de um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.